Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: ADAMTS9-AS1 inhibits tumor growth and drug resistance in clear cell renal cell carcinoma via recruiting HuR to enhance ADAMTS9 mRNA stability

Fig. 2

Promoter hypermethylation contributes to ADAMTS9-AS1 silencing in ccRCC. A-B. The DNA methylation values of ADAMTS9-AS1 were performed in pan-cancer and kidney renal clear cell carcinoma (KIRC) samples from the TCGA database. C. The RNA expression and DNA methylation levels of ADAMTS9-AS1 showed a negative linear correlation in KIRC samples from the TCGA database. D-E. The expression levels of ADAMTS9-AS1 in A498 (D) and 786-O (E) cell lines were obtained by qRT-PCR after treatment with different doses of 5-aza-dC. The data derived from three independent experiments are presented as mean ± SEM in the bar graphs (D-E). Controls were normalized to 1 (D-E). *P < 0.05, **P < 0.01, ***P < 0.001, N.S. not significant

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us